A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 34757794.
- Also identified by DOI 10.1126/sciadv.abj0274 and PMC identifier 8580318.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite recent studies of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), little is known about how the immune response against SARS-CoV-2 differs from other respiratory infections. We compare the immune signature from hospitalized SARS-CoV-2–infected patients to patients hospitalized prepandemic with influenza or respiratory syncytial virus (RSV). Our in-depth profiling indicates that the immune landscape in SARS-CoV-2 patients is largely similar to flu or RSV patients. Unique to patients infected with SARS-CoV-2 who had the most critical clinical disease were changes in the regulatory T cell (T<sub>reg</sub>) compartment. A T<sub>reg</sub> signature including increased frequency, activation status, and migration markers was correlated COVID-19 severity. These findings are relevant as T<sub>regs</sub> are considered for therapy to combat the severe inflammation seen in COVID-19 patients. Likewise, having defined the overlapping immune landscapes in SARS-CoV-2, existing knowledge of flu and RSV infections could be leveraged to identify common treatment strategies.